No Data
No Data
Cellectis SA: Hold Rating Amid Stable Financials and Promising Collaborations, Yet Cautious Outlook Due to Market and Clinical Uncertainties
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
Barclays Maintains Overweight on Cellectis, Lowers Price Target to $4
Cellectis Analyst Ratings
Barclays Maintains Cellectis(CLLS.US) With Buy Rating, Cuts Target Price to $4
Cellectis Cash Position of $246 M as of March 31 Provides Runway Into 2H of 2027